Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats

Circulation Journal

Volumn 73, Issue 9, 2009, Pages 1722-1730

  Sun, Cheuk Kwan ^a   Yuen, Chun Man ^a   Kao, Ying Hsien ^a   Chang, Li Teh ^b   Chua, Sarah ^c   Sheu, Jiunn Jye ^a   Yen, Chia Hung ^c   Ko, Sheung Fat ^a   Yip, Hon Kan ^a,d  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b MEIHO UNIVERSITY   (Taiwan)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Monocrotaline; Propylthiouracil; Pulmonary arterial hypertension

Indexed keywords

CASPASE 3; CONNEXIN 43; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; MESSENGER RNA; MONOCROTALINE; PROPYLTHIOURACIL; PROTEIN BCL 2; PROTEIN KINASE C EPSILON; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; ATTENUATION; BRAIN MICROCIRCULATION; CONTROLLED STUDY; HEART RIGHT VENTRICLE; HEART WEIGHT; LUNG; LUNG ALVEOLUS; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SPRAGUE DAWLEY RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOLES; CASPASE 3; CONNEXIN 43; DISEASE MODELS, ANIMAL; HEART VENTRICLES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MATRIX METALLOPROTEINASE 9; MONOCROTALINE; NITRIC OXIDE SYNTHASE TYPE III; PROPYLTHIOURACIL; PROTEIN KINASE C-EPSILON; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

EID: 69549130512     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0074     Document Type: Article

References (40)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Branzi A, Manes A, Galie N. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc dis 2002; 45: 213-224. (Pubitemid 36139817)
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003; 361: 1533-1544.
4. Gaine SP, Rubin L. Primary pulmonary hypertension. Lancet 1998; 352: 719-725.
5. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, et al. Histopathology of primary pulmonary hypertension: A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206. (Pubitemid 19282508)
6. Ikeda D, Tsujino I, Sakaue S, Ohira H, Itoh N, Kamigaki M, et al. Pilot study of short-term effects of a novel long-acting oral beraprost in patients with pulmonary arterial hypertension. Circ J 2007; 71: 1829-1831. (Pubitemid 350240113)
7. Hiramoto Y, Shioyama W, Kuroda T, Masaki M, Sugiyama S, Okamoto K, et al. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension. Circ J 2007; 71: 367-369. (Pubitemid 46409540)
8. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research "Work in progress". Circulation 2000; 102: 2781-2791.
9. Liu H, Liu ZY, Guan Q. Oral sildenafil prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Interact Cardiovasc Thorac Surg 2007; 6: 608-613. (Pubitemid 47598511)
10. Ogata T, Shibagaki T, Kamma H, Yokose T, Lizima T. Alveolar damage: From epithelial damage and endothelial damage. J Toxicol Pathol 1989; 2: 223-240.
11. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: Efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005; 96: 442-450. (Pubitemid 40354538)
12. Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, et al. Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Crit Care Med 2008; 36: 873-880.
13. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by monocrotaline intoxication. Am J Physiol 1981; 240: H149-H155.
14. Hicks M, Wong LS, Day RO. Antioxidant activity of propylthiouracil. Biochem Pharmacol 1992; 43: 439-444.
15. Chen WJ, Ho WJ, Chang GJ, Chen ST, Pang JH, Chou SH, et al. Propylthiouracil, independent of its antithyroid effect, produces endothelium-dependent vasodilatation through induction of nitric oxide bioactivity. Atherosclerosis 2008; 196: 383-390.
16. Grieve DJ, Fletcher S, Pitsillides AA, Botham KM, Elliott J. Effects of oral propylthiouracil treatment on nitric oxide production in rat aorta. Br J Pharmacol 1999; 127: 1-8. (Pubitemid 29213225)
17. Chen WJ, Lin KH, Lai YJ, Yang SH, Pang JHS. Protective effect of propylthiouracil independent of its hypothyroid effect on atherosclerosis in cholesterol-fed rabbits: PTEN induction and inhibition of vascular smooth muscle cell proliferation and migration. Circulation 2004; 110: 1313-1319.
18. Chen WJ, Pang JH, Link KH, Yang SH. Propylthiouracil, independently of its antithyroid effect, decreases VSMC collagen expression. Basic Res Cardiol 2009; 104: 60-68.
19. Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, Lee FY, et al. Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circ J 2008; 72: 825-831.
20. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
21. Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chau S, et al. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004; 126: 1417-1422.
22. Chen YM, Tu CJ, Hung KY, Wu KD, Tsai TJ, Hsieh BS. Inhibition by pentoxifylline of TNF-α-stimulated fractalkine production in vascular smooth cells: Evidence for mediation by NF-kappa; down-regulation. Br J Pharmacol 2003; 138: 950-958.
23. Chen YM, Chiang WC, Lin SL, Wu KD, Tsai TJ, Hsieh BS. Dual regulation of tumor necrosis factor-α-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappa; and activator protein-1: Modulation by type III phosphodiesterase inhibition. J Pharmacol Exp Ther 2004; 309: 978-986.
24. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 2372-2379. (Pubitemid 351949764)
25. El-Bizri N, Wang L, Merklinger SL, Guignabert C, Desai T, Urashima T, et al. Smooth muscle protein 22alpha-mediated patchy deletion of Bmprla impairs cardiac contractility but protects against pulmonary vascular remodeling. Circ Res 2008; 102: 380-388. (Pubitemid 351271659)
26. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, et al. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 896-905. (Pubitemid 351600668)
27. Sage E, Mercier O, Van den Eyden F, de Perrot M, Barlier-Mur AM, Dartevelle P, et al. Endothelial cell apoptosis in chronically obstructed and reperfused pulmonary artery. Respir Res 2008; 9: 19.
28. Tuder RM, Yeager ME, Geraci M, Golpon HA, Voelkel NF. Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene. Eur Respir J 2001; 17: 1065-1069. (Pubitemid 32717459)
29. Albert CJ, Ford DA. Protein kinase C translocation and PKC-dependent protein phosphorylation during myocardial ischemia. Am J Physiol 1999; 276: H642-H650. (Pubitemid 29100633)
30. Ping P, Zhang J, Qiu Y, Tang XL, Manchikalapudi S, Cao X, et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 1997; 81: 404-414. (Pubitemid 27362528)
31. Ping P, Takano H, Zhang J, Tang XL, Qiu Y, Li RC, et al. Isoform-selective activation of protein kinase C by nitric oxide in the heart of conscious rabbits: A signaling mechanism for both nitric oxide-induced preconditioning. Circ Res 1999; 84: 587-604. (Pubitemid 29138595)
32. Uzzaman M, Honjo H, Takagishi Y, Emdad L, Magee AI, Severs NJ, et al. Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline-induced pulmonary hypertension. Circ Res 2000; 86: 871-878. (Pubitemid 30246984)
33. Blackburn JP, Peter NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1219-1228.
34. Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Aterioscler Thromb Vasc Biol 1997; 17: 3174-3184. (Pubitemid 28016074)
35. Lowenstein CJ, Dinerman JL, Snydel SH. Nitric oxide: A physiological messenger. Ann Intern Med 1994; 120: 227-237. (Pubitemid 2038979)
36. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide vascular remodeling. J Clin Invest 1998; 101: 731-736. (Pubitemid 28096068)
37. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 2009; 27: 322-331.
38. Said SI. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann NY Acad Sci 2008; 1144: 148-153.
39. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-244.
40. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, et al. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295: L789-L799.